Literature DB >> 2078999

Atrial fibrillation. The therapeutic options.

R V Lewis1.   

Abstract

Atrial fibrillation (AF) is a common cardiac arrhythmia which is particularly prevalent among the elderly. In patients with AF of recent onset, restoration of sinus rhythm may be feasible and this can be achieved by DC cardioversion, or by the use of one of a number of drugs including amiodarone, flecainide or propafenone. Neither digoxin nor the calcium antagonists facilitate the restoration of sinus rhythm. Recurrence of AF is common after successful cardioversion and, although long term antiarrhythmic drug therapy may help to maintain sinus rhythm, all such drugs are potentially toxic and can have important proarrhythmic actions. In patients with chronic AF, restoration of sinus rhythm is rarely possible and treatment is directed towards control of the ventricular response rate, which may be achieved with digoxin and/or a rate-limiting calcium antagonist such as verapamil or diltiazem; beta-blockers may also be used although they appear to impair effort tolerance. In addition, long term anticoagulation may be indicated to reduce the risks of systemic embolisation, even in patients with 'nonrheumatic' AF; antiplatelet drugs are of no apparent value in this context. A minority of patients present with AF associated with ventricular pre-excitation; in these individuals both digoxin and the calcium antagonists are contraindicated and the ventricular response rate should be controlled with flecainide, amiodarone or propafenone.

Entities:  

Mesh:

Year:  1990        PMID: 2078999     DOI: 10.2165/00003495-199040060-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  51 in total

1.  ATRIAL CONTRIBUTION TO CARDIAC OUTPUT IN COMPLETE HEART BLOCK.

Authors:  P SAMET; W H BERNSTEIN; D A NATHAN; A LOPEZ
Journal:  Am J Cardiol       Date:  1965-07       Impact factor: 2.778

2.  Clinical experience with amiodarone for treatment of recurrent ventricular tachycardia and ventricular fibrillation.

Authors:  J J Heger; E N Prystowsky; W M Miles; D P Zipes
Journal:  Br J Clin Pract Suppl       Date:  1986-04

3.  Echocardiographic features of atrioventricular and ventriculoatrial conduction.

Authors:  M Naito; L S Dreifus; T J Mardelli; C C Chen; D David; E L Michelson; V Marcy; J Morganroth
Journal:  Am J Cardiol       Date:  1980-10       Impact factor: 2.778

4.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

5.  Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response.

Authors:  B Strasberg; A Arditti; S Sclarovsky; R F Lewin; B Buimovici; J Agmon
Journal:  Int J Cardiol       Date:  1985-01       Impact factor: 4.164

Review 6.  Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects.

Authors:  E M Antman; P H Stone; J E Muller; E Braunwald
Journal:  Ann Intern Med       Date:  1980-12       Impact factor: 25.391

7.  Perceived exertion and gas exchange after calcium and beta-blockade in atrial fibrillation.

Authors:  J Myers; J E Atwood; M Sullivan; S Forbes; R Friis; W Pewen; V Froelicher
Journal:  J Appl Physiol (1985)       Date:  1987-07

8.  Effect of beta-adrenergic blockade on exercise performance in patients with chronic atrial fibrillation.

Authors:  J E Atwood; M Sullivan; S Forbes; J Myers; W Pewen; H G Olson; V F Froelicher
Journal:  J Am Coll Cardiol       Date:  1987-08       Impact factor: 24.094

9.  Usefulness of propafenone for recurrent paroxysmal atrial fibrillation.

Authors:  S J Connolly; D L Hoffert
Journal:  Am J Cardiol       Date:  1989-04-01       Impact factor: 2.778

10.  Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. The Diltiazem-Atrial Fibrillation/Flutter Study Group.

Authors:  D M Salerno; V C Dias; R E Kleiger; V H Tschida; R J Sung; M Sami; L V Giorgi
Journal:  Am J Cardiol       Date:  1989-05-01       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.